Overview

Update
Status
Acquired by on December 14, 2009
Headquarters:
San Mateo, California
Description:
Calixa Therapeutics, a biopharmaceutical company, develops a novel cephalosporin to address the problem of multi-drug resistant organisms.
Founders:
Categories:
Biotechnology
Website:
http://www.calixainc.com

Company Details

Update

Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community.

Calixa’s lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a β-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms.

Current Team (2)

Update

Offices/Locations (1)

Update
  • Office

    1840 Gateway Drive

    Suite 200

    San Mateo, California 94404

    United States

Past Team (2)

Update

Images (1)

Update

Add Funding Rounds

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos